• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
COVID-19 Management

Meta-analysis of Hydroxychloroquine for the Treatment of COVID-19

image_pdfFavoriteLoadingFavorite

PURPOSE:

  • Singh et al. (Diabetes Metabolic Syndrome, 2020) sought to determine the efficacy of hydroxychloroquine (HCQ) compared to the control in COVID-19

METHODS:

  • Meta-analysis
  • Search conducted in PubMed, Scopus, Cochrane and MedRxiv database were searched using the specific keywords (through April 30, 2020)
  • Study inclusion criteria
    • Hydroxychloroquine used in patients with COVID-19 and compared to control | Results include ≥1 outcome of interest (Viral clearance and/or death due to all causes)
    • COVID-19 infection documented with RT-PCR
  • Study exclusion criteria
    • Case reports | Preclinical studies | Outcomes of interest not included |HCQ not compared to placebo or control
  • Study design
    • Meta-analysis performed to identify relationship between HCQ and
      • Viral clearance
      • Death due to all causes
    • 4 reviewers assessed studies for risk of bias (independent analysis)
    • Risk ratio calculated using random-effects model

RESULTS:

  • The authors provide an in-depth literature review of 10 studies that assessed the efficacy and safety of HCQ in patients with COVID-19
  • 7 studies initially selected that compared HCQ to a control in COVID-19 patients
  • 3 studies with specific outcomes of interest

HCQ and Viral Clearance

  • 3 studies included | n = 210 | 2 RCTs and a non-randomized trial
  • HCQ showed no benefit (p=0.74)
    • RR: 1.05 (95% CI, 0.79 to 1.38)

HCQ and Death

  • 3 studies included | n = 474 | 2 Retrospective and 1 RCT
  • HCQ was associated with increased risk of death vs controls (p = 0.002)
    • RR: 2.17 (95% CI, 1.32 to 3.57)

CONCLUSION:

  • In this study HCQ did not hasten viral clearance and may be associated with a twofold risk of death from all causes in patients with COVID-19
  • The authors acknowledge study limitations including
    • Small overall ‘n’ | No individual patient data | Combination of randomized and non-randomized data | Some data pre-print publications | Data could not be sufficiently adjusted for confounders
    • There are studies that suggest improvement of pneumonia and chest imaging findings
  • The authors conclude that

Despite several limitations of this meta-analysis, we feel this finding would instill some degree of skepticism and shall help in curbing the exuberant use of over enthusiastically claimed “magical” drug

Hopefully, large randomized controlled trial such as DISCOVERY (EudraCT 2020-000936-23) and RECOVERY (UK), that is currently studying the effect of HCQ in COVID-19 and comparing it with other anti-viral drugs will finally decide its fate

Learn More – Primary Sources:

Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-Analysis

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

Try it Free »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

NIH COVID-19 Treatment Guidelines
COVID-19: Category Definitions, Symptoms and Those at Increased Risk
Remdesivir Emergency Authorization: FDA Update and Summary of Preliminary NIH Study Data

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site